本帖最后由 老马 于 2012-1-13 21:20 编辑
* i8 F* J9 ^6 \, \' t4 G- B, E8 ]& h' ^, ]/ x8 I! Y
爱必妥和阿瓦斯丁的比较
. E7 W. G# c4 c3 L# S) k
3 e4 l0 G" ]7 x3 _8 O
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/9 T8 p( F. m- U. a- P# T0 i0 V+ m
( U7 x4 G2 ^" M* C+ w/ l
1 w* A9 ?) \; @: C* d
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/ L* H$ C/ ?2 x; E9 Y% B9 ^% g
==================================================& u. }' ], a/ m6 ]8 h% A5 y
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
2 |/ k# K: \+ H/ v; k3 C* S; yPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
+ g8 M3 V8 B rResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
s$ ^( K* P8 H3 H. y
|
显身卡
